Submit Your Feeds

Business News • PR NewsWire • BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors

BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors
BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors

LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer, today announced that the earlier communicated phase l/lla clinical trial...

View More : https://www.prnewswire.com:443/news-releases/bioinvent-will-conduct-phase-llla-trial-with-bi-1206-in-combination-with-pe...
Releted News by prnewswire
Itiviti and Blaze Portfolio Partner to Deliver Superior Trading Connectivity and TCA Services
Nordic Nanovector Appoints Dr Lars Nieba as Chief Technology Officer
BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors
Gatling Drills High-Grade, Near Surface Gold at Cheminis Deposit Including 12.3 g/t Au over 5.0 meters
A Future Design Classic: 'Pura Vision' Model Revealed to Automobili Pininfarina Clients
Home Sitemap Contact Us
© businessNewsNewsNews.com